Gapping up
In reaction to earnings/guidance:
- BNS +0.8%
M&A news:
- CLDR +24.7% (to be acquired by Clayton, Dubilier & Rice and KKR for $5.3 bln ($16.00 in cash per share))
- CLAR +5.5% (to acquire Australia-based Rhino-Rack Pty Ltd, for an aggregate purchase price of ~$198 mln )
Other news:
- LCTX +14.3% (reports additional cases of retinal tissue restoration in Dry AMD patients treated with OpRegen RPE Cells)
- AMC +11.9% (discloses that market prices and trading volume of shares of Class A common stock have recently experienced, and may continue to experience, extreme volatility)
- AKBA +11.1% (and Otsuka announce FDA acceptance for filing of new drug application for vadadustat for the treatment of anemia due to chronic kidney disease in adult patients on dialysis and not on dialysis)
- ALYA +10.6% (won an information resources project management contract with a Québec government ministry worth CAD 12.4 mln)
- CRBP +9.7% (announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor ß)
- NRXP +8.9% (announces "positive" results for ZYESAMI and submits Emergency Use Authorization Application to US Food and Drug Administration to treat critical COVID-19 in patients suffering from respiratory failure)
- ALKS +7.8% (announces FDA approval of LYBALVI for the treatment of schizophrenia and bipolar I disorder)
- CTIC +7.5% (announced that the FDA has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia; PDUFA Action Date November 30, 2021)
- BYSI +6.1% (announces that the U.S. Food and Drug Administration has accepted for filing, and with Priority Review, the Company's New Drug Application seeking approval for use of plinabulin in combination with granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia)
- AFG +5.6% (closes on sale of its annuity businesses for $3.5 bln; declares special one-time dividend of $14.00 per share)
- XPEV +4.7% (reports May deliveries +483% Y/Y
- NIO +4% (reports May deliveries +95.3% yr/yr to 6,711 vehicles)
- JKS +3.7% (announced that the maximum solar conversion efficiency of its large-area N-type monocrystalline silicon solar cells reached 25.25%, setting a new world record for large-size contact-passivated solar cells)
- GSS +3.3% (completes upsizing and restructuring of senior secured credit facility into a revolving credit facility)
- EQNR +2.4% (and ExxonMobil (XOM) Petrogal Brasil and Pré-sal Petróleo have decided to develop phase one of the Bacalhau field in the Brazilian pre-salt Santos area )
- BP +1.9% boosts its renewables business in the US with 9GW solar acquisition from 7X Energy)
- GEO +1.9% (Chairman, Chief Executive Officer and Founder, George C. Zoley, will transition to the position of Executive Chairman of GEO's Board of Directors under a new five-year employment agreement)
- AMGN +1.7% (and Kyowa Kirin to jointly develop and commercialize KHK4083, a Phase 3-ready, potential first-in-class treatment for atopic dermatitis),
Analyst comments:
- INSE +4.7% (initiated with a Buy at B. Riley Securities)
- VALN +4.3% (initiated with a Buy at Guggenheim)
- AFRM +3.8% (upgraded to Buy from Neutral at BofA Securities)
- DVN +3.6% (upgraded to Strong Buy from Outperform at Raymond James)
- WDH +3.3% (Initiated with a Buy at both BofA and Goldman)
- AMRS +2.2% (Initiated with a Buy at HSBC)
- BA +1.8% (upgraded to Outperform from Market Perform at Cowen)
- ISRG +1.4% (upgraded to In-line from Underperform at Evercore)
- SPT +1.3% (resumed with an Overweight at KeyBanc)
- BWMN +1.2% ( initiated with a Buy at B. Riley Securities)